Drugs / NBP607-V
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02467842 Comparator | Oct → Dec 2014 | influenza | SK Chemicals Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBP607-V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02467842 ↗ |
| Modality | Vaccine | “cell culture-based trivalent inactivated influenza vaccine-Victoria (NBP607-V)” PMID 28406746 ↗ Apr 2017 |
| Route | Intramuscular | “Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains;...” NCT02467842 ↗ |